Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : STEM -- StemCells, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (208)	2/6/1999 8:54:00 AM
From: Mike McFarland	Read Replies (1) \| Respond to of 805

more reading material eurekalert.org I've snipped out a few lines, this is just really cool amazing daring stuff...suggests to me that ctii is in an area which is not science fiction-- part of the reason I think some of these stem cell companies etc are not attracting investors is that it all sounds just to incredible to believe. In the treatment, two to six million cells are transplanted in and around the stroke-damaged areas of the brain. The primary goal of this trial is to determine whether the therapy is safe and can be tolerated by patients. "It's difficult to say whether the functional gains some patients have described are due to what we've done or something else." The brain cells used for the treatment are provided by Layton Bioscience, Inc. LBS-neurons, as the laboratory-grown cells are called, originate from human tumor tissue composed of embryonic-like cells.